Home > Insider Trading > Filing (0001209191-14-008037)

Filing Details

Accession Number:: 0001209191-14-008037
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2014-02-06 16:30:32
Reporting Period:: 2014-02-04

Filing Date:: 2014-02-06
Accepted Time:: 2014-02-06 16:30:32
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1305253	Celladon Corp	CLDN	Biological Products, (No Disgnostic Substances) (2836)	330971591

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1473930	Todd Foley	C/O Mpm Asset Management 200 Clarendon Street, 54Th Floor Boston MA 02116		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2014-02-04	943,797	$0.00	943,797	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2014-02-04	11,370	$8.00	955,167	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2014-02-04	111,608	$8.00	1,066,775	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A-1 Convertible Preferred Stock	Disposition	2014-02-04	11,788,047	$0.00	943,797	$0.00
Common Stock	Convertible Promissory Notes	Disposition	2014-02-04	11,370	$8.00	11,370	$8.00
Series A-1 Preferred Stock	Warrant to Purchase Series A-1 Preferred Stock-Right to Buy	Disposition	2014-02-04	218,806	$0.00	218,806	$0.45
Common Stock	Warrant to Purchase Common Stock-Right to Buy	Acquisiton	2014-02-04	17,517	$0.00	17,517	$5.61

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
0			No	4	C	Indirect
0	2013-10-15	2018-10-15	No	4	C	Indirect
17,517	2013-10-15	2018-10-15	No	4	C	Indirect

Footnotes

The shares are held as follows: 884,566 by MPM BioVentures IV-QP, L.P. ("BV IV QP"), 34,078 by MPM BioVentures IV GmbH & Co. Beteiligungs KG ("BV IV KG") and 25,153 by MPM Asset Management Investors BV4 LLC ("AM BV4"). MPM BioVentures IV GP LLC and MPM BioVentures IV LLC ("BV LLC") are the direct and indirect general partners of BV IV QP and BV IV KG and BV LLC is the manager of AM BV4. The Reporting Person is a member of BV LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
Each share of Series A-1 Preferred Stock automatically converted into 0.080064 of Common Stock without payment of further consideration upon the closing of the Issuer's initial public offering ("IPO"). The shares had no expiration date.
Represent the conversion of outstanding promissory notes in the principal amount of $89,313.48, plus interest accrued at 6% per annum, which became convertible at $8.00 per share, and simultaneously automatically converted into shares of the Issuer's Common Stock, upon the closing of the IPO. The principal amount of the notes were held as follows: $83,708.25 by BV IV QP, $3,224.93 by BV IV KG and $2,380.30 by AM BV4 and the principal and interest converted into the following shares of Common Stock: 10,657 by BV IV QP, 410 by BV IV KG and 303 by AM BV4.
The shares are held as follows: 895,223 by BV IV QP, 34,488 by BV IV KG and 25,456 by AM BV4. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
The shares were purchased as follows: 104,603 by BV IV QP, 4,030 by BV IV KG and 2,975 by AM BV4.
The shares are held as follows: 999,826 by BV IV QP, 38,518 by BV IV KG and 28,431 by AM BV4. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
Immediately.
Not applicable.
The shares of Series A-1 Preferred Stock were held as follows: 11,048,241 by BV IV QP, 425,642 by BV IV KG and 314,164 by AM BV4.
The principal and interest converted into the following shares of Common Stock: 10,657 by BV IV QP, 410 by BV IV KG and 303 by AM BV4.
Represents the automatic conversion of warrants to purchase Series A-1 Preferred Stock into warrants to purchase Common Stock on a 1-for-12.49 basis upon the closing of the IPO.
The warrants were held as follows: 205,075 by BV IV QP, 7,900 by BV IV KG and 5,831 by AM BV4.
The warrants are held as follows: 16,419 by BV IV QP, 632 by BV IV KG and 466 by AM BV4. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.